This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice. Boehringer Ingelheim Limited has reviewed the scope of the webinar, commissioned the speaker, and approved all materials related to the webinar. The speaker has been paid an honorarium. The views and opinions of the speaker are not necessarily those of Boehringer Ingelheim Limited, or of Guidelines in Practice, its publisher, advisers, or advertisers.
The webinar is intended for UK healthcare professionals.
This webinar was planned before the publication of the COVID-19 guidance from the NHS. Please refer to local and national guidelines for the latest recommendations.
If you do not wish to complete the feedback form, please email email@example.com to request your certificate
This 1-hour Guidelines in Practice webinar reviews:
- current use of ICS in the UK
- the benefits and risks of ICS
- the role of blood eosinophils to identify patients who would benefit from ICS
- the place of ICS in current guidelines
- the role of bronchodilators.
Feedback from live webinar attendees
‘Wonderful presentation and definitely changed my practice for sure!’
‘Speaker was excellent: clear, concise, and easy to understand.’
‘Very good. Feel like I learnt a lot in a short time.’
‘Thought-provoking presentation with lots of take-home messages.’
‘Really excellent, thank you. Clearly presented and backed up with “digestible” research. So helpful!’
Professor James Chalmers
British Lung Foundation Professor of Respiratory Research,
University of Dundee
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).
Date of preparation: June 2020